Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704871 · ClinicalTrials.gov registry record
The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS
A clinical trial, sponsored by Immunexpress.
- Terminated
- Registry status
- 66
- Enrollment target
NCT02704871 is a clinical trial that was terminated before completion, run by Immunexpress. The registered enrollment target is 66 participants.
The verdict
NCT02704871 was terminated before completion, sponsored by Immunexpress.
- TERMINATED
- Registry status
- 66 participants
- Enrollment target
Study Summary
A non-interventional, prospective observational study to assess the performance of SeptiCyte® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS
Interventions
- OTHER SeptiCyte Lab molecular diagnostic test (non-interventional)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02704871
The ClinicalTrials.gov registry entry for NCT02704871 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunexpress, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SeptiCyte Lab molecular diagnostic test (non-interventional) is the first listed.
NCT02704871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02704871 about?
NCT02704871 is a clinical study titled "The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS". A non-interventional, prospective observational study to assess the performance of SeptiCyte® Lab to diagnose patients identified as suspected of sepsis in general medical and surgical wards with infection-positive from infection-negative SIRS
What is the current status of trial NCT02704871?
This trial is currently terminated. The enrollment target is 66 participants. The study started on 2015-06. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02704871?
The interventions under investigation include: SeptiCyte Lab molecular diagnostic test (non-interventional) (OTHER).
Who is sponsoring clinical trial NCT02704871?
This trial is sponsored by Immunexpress, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.